Nour Abuhadra, MD
Breast Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
About Me
- Director, Rare Breast Cancer Program, Department of Medicine
- Co-Section Head, Triple Negative Breast Cancer Clinical Research Program, Department of Medicine
I am a board-certified medical oncologist whose clinical practice is dedicated to the care of patients with breast cancer. My practice is located in the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center.
Read more
My familiarity with breast cancer predated any medical training. Awareness of the most prevalent cancer in women had always been packaged in the form of fundraisers, marathons, and pink paraphernalia — a campaign I supported long before I realized that awareness was just the tip of the pink ribbon. As I met the women whose lives had been impacted by this disease, it shifted my mindset — I felt an obligation to turn that awareness into action. Now, as a breast medical oncologist, I am privileged to turn that awareness into action every day.
In addition to my clinical practice, I am also a clinical investigator, and my research focuses on characterizing the immune microenvironment of breast tumors to inform treatment selection. I have a special interest in triple-negative breast cancer and rare breast cancer types, in particular, an aggressive subtype known as metaplastic breast cancer. As our understanding of breast cancer evolves, it is exceedingly clear that therapy is not one-size-fits-all. Therefore, personalizing care will undoubtedly improve patient outcomes and quality of life. Not only will our patients have a better response when treatment is tailored to their specific tumor biology but also a better side-effect profile when they are only receiving treatment that is necessary. I have presented some of these research findings at national and international conferences, including the American Society of Clinical Oncology, European Society of Medical Oncology, and San Antonio Breast Cancer Symposium.
I work closely with my colleagues in breast imaging, surgical oncology, radiation oncology, and plastic surgery to deliver the highest quality of care. I am dedicated to guiding my patients through their diagnosis, providing clear and comprehensive education on treatment options, including innovative clinical trials that are available at MSK. My goal at the end of every clinic visit is for my patients to have a clear understanding of what lies ahead. I want them to feel confident in their personalized treatment plan and empowered to make informed decisions on their cancer care. Above all else, my patients will leave clinic knowing that our entire team is here to help them navigate this journey together.
A breast medical oncologist is a cancer doctor who specializes in breast cancer.
My Specialties
- Breast Cancer
Education
- MD, Weill Cornell Medical College
Residencies
- Internal Medicine - Cleveland Clinic Foundation
Awards and Honors
- Conquer Cancer Career Development Award, ASCO (2023)
- Conquer Cancer Foundation Merit Award, the American Society of Clinical Oncology (ASCO, 2019-2021)
- Susan Papizan Dolan Fellowship in Breast Oncology (2020)
- AACR Associate Member Award (2020)
- Sheskey Family Endowed Fellowship in Breast Cancer Research (2021)
Fellowships
- Hematology/Oncology - MD Anderson Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Abuhadra sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Abuhadra
- A Phase 1 Study of XMT-1660 in People with Advanced Solid Tumors (Triple-Negative Breast Cancer)
- Clinical Trials Co-Investigated by Dr. Abuhadra
- A Phase 1 Study of Pembrolizumab Immunotherapy and Cryoablation in People With Advanced Breast Cancer
- A Phase 3 Study of Datopotamab Deruxtecan With or Without Durvalumab Versus Investigator¿s Choice of Therapy in People with Stage 1-3 Triple-Negative Breast Cancer Remaining in the Breast and/or Lymph Nodes After Presurgical Chemotherapy
- A Phase I/II Study of REGN7075 plus Cemiplimab Immunotherapy in People with Advanced Solid Tumor Cancers
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Abuhadra’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Nour Abuhadra discloses the following relationships and financial interests:
-
Boxer Capital, LLC
Professional Services and Activities -
Medscape
Professional Services and Activities
-
MJH Life Sciences
Professional Services and Activities -
OncLive
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].